Summary
The product BOLD 200, manufactured by Unique Pharma, was independently tested to verify its authenticity and potency. The sample, identified by batch number UN56437, was submitted by the reseller Opitropin.EU and analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical quality control. The analysis measured the presence of Boldenone Undecylenate, with a concentration of 193.20 mg/ml, falling 3.40% below the labeled claim of 200 mg/ml.
The testing process commenced on 14 September 2023, with the sample received on 18 September 2023, and the analysis completed on 21 September 2023. While the results indicate a slight underdose, it is important to consider that reseller-submitted samples may represent high-quality batches that do not necessarily reflect overall market consistency. Independent third-party testing remains essential to validate these findings comprehensively. This report serves as an educational resource to promote harm reduction and informed decision-making.
Detailed Report
Product Overview
- Manufacturer: Unique Pharma
- Product Name: BOLD 200
- Active Ingredient: Boldenone Undecylenate
- Batch Number: UN56437
- Expiration Date: Not provided
- Delivery Method: Injectable
Sample Acquisition and Testing
- Task Number: #33797
- Testing Ordered: 14 September 2023
- Sample Received: 18 September 2023
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Opitropin.EU (Reseller)
- Analysis Paid For By: Opitropin.EU
Testing Results
- Specification: 200 mg/ml (as stated on the label)
- Measured Concentration: 193.20 mg/ml
- Accuracy: 96.60% (3.40% below the label claim)
- Variance: -3.40%
Verification Details
- Verification URL: www.janoshik.com/tests/33797_ELVCI4Z1JV6G
- Originally Published: https://thinksteroids.com/community/posts/3118518/
Evaluation of Reseller-Submitted Testing
This analysis confirms that the tested product falls slightly below its labeled claim. However, since the sample was submitted and funded by the reseller Opitropin.EU, there is a possibility that high-quality batches were selectively chosen for analysis. To ensure a comprehensive understanding of the product’s consistency, further third-party testing across multiple batches is recommended.
Conclusion
The analysis of BOLD 200 confirms a measured concentration of 193.20 mg/ml, reflecting a minor deviation from the label claim. This suggests relatively consistent quality control for this batch; however, the observed variance highlights the need for additional testing to ensure consistent dosing across production batches. This report aims to support educational and harm reduction efforts, helping consumers make informed choices.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may introduce inherent biases; however, it still provides useful insights when critically assessed alongside independent third-party results. Readers are encouraged to use this information responsibly.
